SIGA Technologies, Inc. · New York, NY United States (NASDAQ: SIGA)
| 420 Lexington Ave., Ste. 408 | Phone: 212-672-9100 |
| New York, NY | Fax: 212-697-3130 |
| 10170 | |
| United States | 
Map This Company |
SIGA Technologies, Inc. Rankings
More Companies in These Related Industries: Company Description
SIGA Technologies is trying to put itself on the front lines of US biodefense efforts. The drug company has a number of development programs for vaccines, antivirals, and antibiotics for drug resistant infections; however, its main focus is on vaccines for bio-defense. The company's smallpox vaccine ST-246, which is intended both to prevent and treat the disease, has received Fast Track and Orphan Drug designations from the FDA. SIGA is also developing vaccines for use against hemorrhagic fevers and other infectious diseases and biothreats. Much of its work is done through funding from the
SIGA Technologies, Inc. Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | Public - NASDAQ: SIGA Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2010 Employees | 65 |
Executives
16 executives listed for SIGA Technologies, Inc.'s New York, NY location.
| Chairman and CEO | Eric Rose | |
|---|---|---|
| EVP and CFO | Daniel Luckshire | |
| VP and Chief Scientific Officer | Dennis Hruby |